Trial Profile

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HBAI 20 (Primary) ; Hepatitis B vaccine recombinant (HBvaxPro)
Indications Hepatitis B
Focus Adverse reactions

Most Recent Events

13 Sep 2016 Status changed from active, no longer recruiting to completed.
29 Apr 2016 According to a CyTuVax media release, all subjects have been vaccinated twice and the data from this trial will be published in the third quarter of 2016.
29 Apr 2016 Interim results for non-responders published in the CyTuVax media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com